General Info

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since it s founding in 2000, the company has built a fully integrated set of capabilities in monoclonal antibody product development. The company s product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual Affinity Re-Targeting (DART), which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. These powerful sets of capabilities and technology platforms have enabled MacroGenics to build a proprietary pipeline of innovative product candidates.